Bolt Biotherapeutics, Inc. BOLT
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) is an oncology drug developer. Its lead program, BDC-4182, is in Phase 1 for claudin 18.2-positive gastric/gastroesophageal junction cancer.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BDC-4182 (claudin 18.2 Boltbody ISAC) | gastric/GEJ cancer | antibody | Phase 1 |
| BDC-3042 (dectin-2 agonist antibody) | solid tumors | antibody | Phase 1 |
| CEA ISAC | CEA-expressing solid tumors | antibody | Pre-clinical |
| PD-L1 ISAC | PD-L1-expressing tumors | antibody | Pre-clinical |
Recent results and decisions
- Oct 23, 2026n/a Bolt Biotherapeutics acquired Prana Therapies, Inc. through a two-step merger completed on October 23, 2026.
First Merger Sub merged with and into Prana, pursuant to which Prana was the surviving corporation and became a wholly owned subsidiary of the Company.
Filing - Oct 23, 2026n/a Bolt Biotherapeutics sold 13,995.311 shares of Series D Preferred Stock convertible into Common Stock plus warrants to purchase additional preferred shares.
The Company desires to sell to the Investors an aggregate of 13,995.311 shares of Series D Non-Voting Convertible Preferred Stock, which will be convertible into shares of the Company's common stock.
Filing - Oct 23, 2026n/a Dr. Sheila Gujrathi was appointed as Chief Strategy Officer of Bolt Biotherapeutics effective immediately after the First Merger.
Effective immediately after the First Effective Time, Dr. Sheila Gujrathi was appointed as the Chief Strategy Officer of the Company.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.